Potential therapeutic applications of microbial surface-activecompounds

Numerous investigations of microbial surface-active compounds or biosurfactants over the past two decades have led to the discovery of many interesting physicochemical and biological properties including antimicrobial, anti-biofilm and therapeutic among many other pharmaceutical and medical applications. Microbial control and inhibition strategies involving the use of antibiotics are becoming continually challenged due to the emergence of resistant strains mostly embedded within biofilm formations that are difficult to eradicate. Different aspects of antimicrobial and anti-biofilm control are becoming issues of increasing importance in clinical, hygiene, therapeutic and other applications. Biosurfactants research has resulted in increasing interest into their ability to inhibit microbial activity and disperse microbial biofilms in addition to being mostly nontoxic and stable at extremes conditions. Some biosurfactants are now in use in clinical, food and environmental fields, whilst others remain under investigation and development. The dispersal properties of biosurfactants have been shown to rival that of conventional inhibitory agents against bacterial, fungal and yeast biofilms as well as viral membrane structures. This presents them as potential candidates for future uses in new generations of antimicrobial agents or as adjuvants to other antibiotics and use as preservatives for microbial suppression and eradication strategies

A new antibacterial and antioxidant S07-2 compound produced by Bacillus subtilis B38

An antibacterial compound, S07-2, was purified to homogeneity by hydrophobic interaction, anion exchange, C18 reverse-phase and HS PEG HPLC. The molecular mass of S07-2 was 905.6 Da as determined by MS. The S07-2 compound was resistant to high temperatures (up to 100 1C) and could withstand a wide range of pH from 3 to 10. In addition, its antibacterial activity was preserved after treatment with proteases. Biochemical characterization revealed its cyclic peptide structure. This compound showed a bactericidal effect against important food- spoilage bacteria and food-borne pathogens including Listeria monocytogenes and Enterococcus faecalis with lethal concentration values of 62.5 mg mL1 and against Salmonella enteritidis at a concentration of 31.25 mg mL1 . However, no cytotoxic effect against human erythrocytes was recorded. Furthermore, the S07-2 com- pound displayed a remarkable Fe 21 -chelating activity (EC50 = 9.76 mg mL1 ) and 1-diphenyl-2-picrylhydrazyl-scavenging capacity (IC50 = 65 mg mL1 ). All these chemical and biological features make S07-2 a useful compound in the food industry as a natural preservative

Synergistic antifungal activity and potential mechanism of action of a glycolipid like compound produced by Streptomyces blastmyceticus S108 against Candida clinical isolates

Ayed A, Essid R, Mankai H, et al. Synergistic antifungal activity and potential mechanism of action of a glycolipid like compound produced by Streptomyces blastmyceticus S108 against Candida clinical isolates. Journal of Applied Microbiology . 2023: lxad246.AIM: The present study aimed to investigate a novel antifungal compound produced by Streptomyces blastmyceticus S108 strain. Its effectiveness against clinical isolates of Candida species and its synergistic effect with conventional antifungal drugs were assessed and its molecular mechanism of action was further studied against C. albicans.; METHODS AND RESULTS: A newly isolated strain from Tunisian soil, Streptomyces blastmyceticus S108, showed significant antifungal activity against Candida species by well diffusion method. The butanolic extract of S108 strain supernatant exhibited the best anti-Candida activity with a minimal inhibitory concentration (MIC) value of 250 mug mL-1, determined by the microdilution method. The bio-guided purification steps of the butanolic extract were performed by chromatographic techniques. Among the fractions obtained, F13 demonstrated the highest level of activity, displaying a MIC of 31.25 mug mL-1. Gas Chromatography-Mass Spectrometry (GC-MS) and Electrospray Ionisation Mass Spectrometry (ESI-MS) analyses of this fraction (F13) revealed the glycolipidic nature of the active molecule with a molecular weight of 685.6 m/z. This antifungal metabolite remained stable to physicochemical changes and did not show hemolytic activity even at 4 MIC corresponding to 125 g mL-1 towards human erythrocytes. Besides, the glycolipid compound was combined with 5-flucytosine and showed a high synergistic effect with a FICI value 0.14 against C. albicans ATCC 10231. This combination resulted in a decrease of MIC values of 5-flucytosine and the glycolipid-like compound by 8 and 64-fold, respectively. The examination of gene expression in treated Candida albicans cells by qPCR revealed that the active compound tested alone or in combination with 5-flucytosine blocks the ergosterol biosynthesis pathway by down regulating the expression of ERG1, ERG3, ERG5, ERG11 and ERG25 genes.; CONCLUSION AND IMPACT OF THE STUDY: The new glycolipid like compound, produced by Streptomyces S108 isolate, could be a promising drug for medical use against pathogenic Candida isolates. © The Author(s) 2023. Published by Oxford University Press on behalf of Applied Microbiology International

Cyclic lipopeptide profile of the plant-beneficial endophytic bacterium Bacillus subtilis HC8

In a previous study (Malfanova et al. in Microbial Biotech 4:523-532, 2011), we described the isolation and partial characterization of the biocontrol endophytic bacterium B. subtilis HC8. Using thin-layer chromatography, we have detected several bioactive antifungal compounds in the methanolic extract from the acid-precipitated supernatant of HC8. In the present study, we have further analyzed this methanolic extract using liquid chromatography-mass spectrometry. Based on the comparison of retention times and molecular masses with those of known antifungal compounds, we identified three families of lipopeptide antibiotics. These include four iturins A having fatty acyl chain lengths of C14 to C17, eight fengycins A (from C14 to C18 and from C15 to C17 containing a double bond in the acyl chain), four fengycins B (C15 to C18), and five surfactins (C12 to C16). Evaluation of the antifungal activity of the isolated lipopeptides showed that fengycins are the most active ones. To our knowledge, this is the first report of an endophytic Bacillus subtilis producing all three major families of lipopeptide antibiotics containing a very heterogeneous mixture of homologues. The questions remain open which of these lipopeptides (1) are being produced during interaction with the plant and (2) are contributing to the biocontrol activity of HC8. © 2012 The Author(s)